The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: Role of Toxic Lipids by de la Monte, Suzanne M. et al.
Int. J. Environ. Res. Public Health 2009, 6, 2055-2075; doi:10.3390/ijerph6072055 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Article 
The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: 
Role of Toxic Lipids 
 
Suzanne M. de la Monte 
1,3-8,*, Lisa Longato 
6,7, Ming Tong 
2,3,6,7,8, Sarah DeNucci 
3,7,8 and Jack 
R. Wands 
2,3,6,7,8 
 
1  Division of Neuropathology, Brown University, Providence, RI, USA 
2  Division of Gastroenterology, Brown University, Providence, RI, USA 
3  Department of Medicine, Brown University, Providence, RI, USA 
4  Department of Pathology, Brown University, Providence, RI, USA 
5  Department of Neurology, Brown University, Providence, RI, USA 
6  The Liver Research Center, Brown University, Providence, RI, USA 
7  Rhode Island Hospital, Brown University, Providence, RI, USA 
8  The Warren Alpert Medical School, Brown University, Providence, RI, USA  
 
E-Mails: Lisa_Longato@Brown.edu (L.L); ming_tong_ming@yahoo.com (M.T.); 
sdenucci1@lifespan.org (S.D.); Jack_Wands_MD@Brown.edu (J.R.W.) 
 
* Author to whom correspondence should be addressed; Tel.: +1-401-444-7364; Fax: +1-401-444-
2939; E-Mail: Suzanne_DeLaMonte_MD@Brown.edu 
Received: 24 June 2009 / Accepted: 16 July 2009 / Published: 23 July 2009 
 
Abstract: Alcohol abuse causes progressive toxicity and degeneration in liver and brain due 
to  insulin  resistance,  which  exacerbates  oxidative  stress  and  pro-inflammatory  cytokine 
activation.  Alcohol-induced  steatohepatitis  promotes  synthesis  and  accumulation  of 
ceramides and other toxic lipids that cause insulin resistance. Ceramides can readily cross 
the  blood-brain  barrier,  and  ceramide  exposure  causes  neurodegeneration  with  insulin 
resistance and oxidative stress, similar to the effects of alcohol. Therefore, in addition to its 
direct neurotoxic effects, alcohol misuse establishes a liver-brain axis of neurodegeneration 
mediated by toxic  lipid trafficking across the blood-brain  barrier,  leading to progressive 
white matter degeneration and cognitive impairment. 
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1. Introduction-Alcoholic Degeneration in Liver and Brain 
 
Alcoholic Liver and Brain Diseases  
 
Alcohol dependence and abuse are among the most costly healthcare problems in the world, and 
their impact continues to grow due to the rising incidence of heavy alcohol drinking among women 
and  young  people.  Excessive  drinking  can  cause  chronic  liver  injury  associated  with  profound 
impairments in hepatocellular regeneration [1-4]. Cirrhosis develops when recurrent injury and cell 
loss  are  not  adequately  counterbalanced  by  repair  mechanisms,  due  to  inhibition  of  DNA  
synthesis [5-10], reduced energy metabolism, insulin resistance, and oxidative stress [11,12]. 
The central nervous system (CNS) is the other major target of alcohol toxicity and degeneration. 
Chronic alcohol abuse causes cognitive impairment with permanent structural damage to the brain. 
Although Wernicke-Korsakoff syndrome is one of the most devastating forms of alcohol-associated 
neurodegeneration, its pathogenesis is largely related to thiamine deficiency [13,14]. In contrast, more 
common  alcohol-related  brain  lesions,  including  white  matter  attrition/degeneration 
(leukoencephalopathy), ventriculomegaly, cerebellar degeneration, and neuronal loss in the superior 
frontal  association  cortex,  anterior  cingulate  region,  hippocampus,  entorhinal  cortex,  and 
hypothalamus, which contribute to cognitive and motor deficits [13-15], are still under investigation, 
although evidence suggests that these pathologies are mediated by insulin resistance [16]. 
 
2. Effects of Alcohol on Insulin and Insulin-like Growth Factor Signaling 
 
Insulin and IGF-1 Actions in Liver and Brain:  
 
Insulin transmits pro-growth and pro-survival signals by activating complex intracellular pathways, 
beginning with ligand binding to cell surface receptors. Subsequent activation of intrinsic receptor 
tyrosine kinases results in tyrosine phosphorylation of the insulin receptor substrate, type 1 (IRS-1), 
which  transmits  signals  downstream  to  promote  growth,  survival,  and  energy  metabolism  [17].  A 
critical  feature  of  the  insulin/IRS  signal  transduction  cascade  is  the  interaction  of  tyrosyl 
phosphorylated (PY) IRS-1 with adaptor molecules that contain src homology domains, such as Grb2 
and the p85 subunit of PI3 kinase, to promote mitogenesis, cell  survival, gene expression, energy 
metabolism, and motility, all of which are needed for liver remodeling and repair after injury [17-19]. 
A  very  similar  signaling  pathway  exists  for  insulin-like  growth  factor  type  1  (IGF-1),  but  at 
physiological concentrations,  insulin and IGF-1 selectively  bind to their own receptors to mediate 
distinct functions.  
In  the  CNS,  insulin/IGF-1  signaling  cascades  have  critical  roles  in  regulating  and  maintaining 
cognitive  and  motor  functions.  Insulin,  IGF-1  and  IGF-2,  and  their  corresponding  receptors  are Int. J. Environ. Res. Public Health 2009, 6                 
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abundantly expressed  in  various cell types throughout the brain,  including neurons  [17,20,21] and 
oligodendroglia [22-24]. Insulin and IGF signaling pathways utilized by CNS neurons are virtually 
identical  to  those  present  in  liver,  except  that  IRS-2  instead  of  IRS-1  is  the  major  docking  
protein [17,25]. The highest levels of insulin and IGF polypeptide and receptor gene expression are 
distributed in the hypothalamus, temporal lobe, and cerebellum [17], i.e., major targets of ethanol-
mediated  neurotoxicity.  Since  insulin  and  IGF  mediate  neuronal  and/or  oligodendroglial  survival, 
plasticity, energy metabolism, and neurotransmitter function [17,26-29], sustained impairments in their 
corresponding signal transduction cascades would have dire consequences with respect to cognition 
and behavior. 
 
Ethanol-Mediated Liver Injury and Degeneration Linked to Inhibition of Insulin and IGF Signaling  
 
Alcohol-induced  liver  injury  is associated with steatohepatitis, which  is  largely reversible when 
alcohol abuse is stopped. Otherwise, steatohepatitis may progress through stages of fibrosis, followed 
by  cirrhosis  and  then  end-stage  liver  disease.  Superimposed  insults,  such  as  obesity,  metabolic 
syndrome, infections with Hepatitis B (HBV) or Hepatitis C (HCV) virus, or hemochromatosis, can 
exacerbate alcoholic liver disease and cause it to progress. Alcohol mediates its adverse effects by 
inhibiting DNA synthesis and thereby impairing the liver’s capacity to regenerate [3,4,30]. In addition, 
repair and survival mechanisms become compromised by increased oxidative stress, DNA damage, 
mitochondrial dysfunction, lipid peroxidation, and pro-inflammatory cytokine activation [12,31,32]. 
These anti-growth and pro-stress cascades are driven, in part, by ethanol's inhibitory effects on insulin 
and IGF-1 signaling [8-11,31]. As the populations of insulin or IGF-1 receptor bearing hepatocytes 
decline, insulin/IGF-1 responsive gene expression and functions deteriorate [11,12].  
We have characterized the effects of chronic ethanol feeding in three rat strains that we found to be 
distinguished by their inherently low (Fisher 344; FS), intermediate (Sprague-Dawley; SD), or high 
(Long Evans; LE) levels of susceptibility to alcohol-induced liver injury. After eight weeks of chronic 
ethanol feeding (37% caloric content, liquid diet), FS rats had minimal injury and hepatic steatosis, SD 
rats had patchy  micro- and macro-steatohepatitis with early  fibrosis, and LE rats had  conspicuous 
micro- and macro-steatohepatitis with apoptotic bodies, disorganized hepatic chord architecture, and 
chickenwire (peri-hepatocyte) fibrosis [12]. 
Biochemical and protein assays showed that ethanol-fed LE rats had the highest hepatic levels of 
neutral lipids and triglycerides, and the lowest levels of insulin receptor binding, while SD rats had 
intermediate values, and FS had the lowest hepatic lipid content and significantly higher levels of 
insulin receptor binding compared with the other two strains (Figure 1). In addition, we noted that 
control LE rat livers had reduced insulin receptor binding relative to control SD and FS rats  [12], 
indicating  that  genetic  factors  most  likely  establish  thresholds  for  hepatic  insulin  resistance,  a 
phenomenon that could account for differences in host susceptibility to alcohol-induced liver injury. 
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Figure 1. Genetic factors govern susceptibility to alcohol-induced liver injury, steatosis, 
and insulin resistance. Fisher 344 (Fisher), Long Evans (LE), and Sprague Dawley (SD) 
rats were fed with control or ethanol containing liquid diets for eight weeks, and then (A) 
serum was obtained to measure to measure alanine aminotransferase (ALT), and  livers 
were harvested to assess (B) lipid content using the Nile Red assay, (C) triglycerides, and 
(D)  insulin  receptor  binding.  (*  P  <  0.05;  ***  P  <  0.001;  FLU  =  fluorescent  light  
units) [11,12]. 
 
 
3. Ethanol-Mediated Insulin Resistance-Mechanisms and Consequences  
 
Chronic Ethanol Abuse Causes Brain Insulin Resistance 
 
Chronic ethanol exposure causes apoptotic and mitochondrial death of insulin/IGF expressing and 
insulin/IGF  receptor  bearing  cells  in  the  brain  [16,33,34].  In  addition,  ethanol  causes  insulin/IGF 
resistance  by  impairing  receptor  binding  [16,35,36].  These  adverse  effects  of  ethanol  are  dose-
dependent. In adult rats and humans, ethanol-induced neurodegeneration in the cerebellum, anterior 
cingulate gyrus (frontal lobe), hypothalamus, and temporal lobe is associated with the same molecular 
and  biochemical  abnormalities  demonstrated  in  liver,  including  insulin  and  IGF-1  resistance  and 
mitochondrial dysfunction [16,35]. Importantly, alcohol-mediated neurodegeneration results in loss of 
neurons and oligodendroglia, decreased mRNA levels of myelin-associated, insulin-responsive, and Int. J. Environ. Res. Public Health 2009, 6                 
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mitochondrial genes, and increased indices of apoptosis, oxidative stress, mitochondrial dysfunction, 
lipid peroxidation, DNA damage, and deregulated acetylcholine homeostasis [35].  
Analysis of temporal lobes and cerebella from LE, SD, and FS rats revealed similar trends with 
respect to severity of alcohol-induced neurodegeneration (Figure 2), including brain insulin resistance, 
oxidative stress, and neuronal and oligodendroglial cell loss. However, unlike liver, the control rats did 
not  differ  by  strain  with  respect  to  baseline  levels  of  insulin  and  IGF  receptor  binding  in  brain. 
Therefore,  increased  susceptibility  to  alcohol-mediated  neurodegeneration  correlates  with  inherent 
strain differences in the levels of insulin/IGF resistance in liver, and the degrees to which ethanol 
increases insulin/IGF resistance in liver and brain-- supporting the concept of a liver-brain axis of 
neurodegeneration.  
 
Figure  2.  Genetic  factors  regulate  severity  of  alcohol-induced  neurodegeneration. 
Cerebella of Fisher (A,B), LE (C,D), and SD (E,F) control (A,C,E) or ethanol (B,D,F) fed 
rats were examined histologically. Control cerebella in each group had a normal tri-laminar 
architecture with intact molecular layer (ml), Purkinje layer (pc and arrows), and granule 
cell (gc) layers. Ethanol feeding had minimal effects on Fisher rat cerebella (B), but caused 
severe  degeneration  of  Purkinje  cell  and  granule  cell  layers  in  LE  greater  than  SD  
rats [16,35,37]. 
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Signaling Pathways Mediating Hepatic and Brain Insulin Resistance  
 
Research  conducted  over the  past  15  years  has  demonstrated that  ethanol  mediates  its  adverse 
effects  on  hepatocytes  and  liver  and  brain  through  inhibition  of  insulin  and  IGF  signaling  
mechanisms [37]. In vitro and in vivo experiments revealed that ethanol inhibits hepatocellular insulin 
signaling  by  reducing  insulin  receptor  binding,  insulin  receptor  tyrosine  phosphorylation,  and 
activation of intrinsic receptor tyrosine kinase. In essence, chronic ethanol exposure causes hepatic 
insulin/IGF-1 resistance [38-43]. Correspondingly, Erk MAPK activation of DNA synthesis and liver 
regeneration  [5,8-10],  and  phosphatidylinositol-3-kinase  (PI3  Kinase)  stimulation  of  cell  growth, 
survival, glucose utilization, and energy metabolism are impaired by chronic ethanol feeding [8,31,44-48]. 
Therefore, chronic ethanol exposure constitutively increases hepatocellular injury, DNA damage, and 
pro-apoptosis mechanisms [31,49,50], while inhibiting insulin/IGF-1 stimulated pathways responsible 
for survival, energy metabolism, regeneration, remodeling, and repair.  
Chronic ethanol exposure also inhibits insulin and IGF signaling mechanisms in the CNS [51-54]. 
As described for liver, ethanol mediates its adverse effects in the CNS by impairing binding to cell 
surface receptors, reducing receptor tyrosine kinase activation, and inhibiting downstream signaling 
through IRS, including activation of insulin/IGF responsive genes [34,36]. In addition, ethanol causes 
oxidative  stress,  DNA  damage,  lipid  peroxidation,  and  mitochondrial  dysfunction,  in  part  due  to 
inhibition of insulin signaling, but also via acetaldehyde-mediated adduct formation [55]. In contrast to 
liver, in the CNS, ethanol disproportionately impairs signaling through PI3 kinase-Akt [33,52,54,56]. 
Correspondingly,  major  adverse  effects  of  ethanol  on  CNS  neurons  include,  reduced  survival  and 
plasticity,  increased  apoptosis  [52,54,57],  and  mitochondrial  dysfunction  with  deficits  in  energy 
metabolism and acetylcholine  homeostasis  [33,52,56,58]. The lopsided  inhibition of PI3K-Akt and 
attendant activation of glycogen synthase kinase 3 (GSK-3) in neurons and brain is partly due to 
ethanol-activation of phosphatases such as PTP-1b and PTEN [59].  
 
Ethanol-Induced Brain Insulin/IGF Resistance Linked to Altered Membrane Lipid Composition 
 
Insulin and IGF signaling are mediated by ligand binding to membrane-anchored receptors. Since 
significant  alterations  in  membrane  lipid  composition  can  impair  receptor  binding  and  subsequent 
downstream signaling [60,61], we tested the hypothesis that ethanol-induced insulin/IGF resistance in 
brain is mediated by altered membrane lipid composition [36]. Our experimental results showed that: 
1) neuronal membrane cholesterol content is reduced by ethanol exposure; 2) methyl--cyclodextrin 
(MCD) depletion of membrane cholesterol impairs insulin receptor binding and insulin-stimulated 
glucose uptake; and 3) cholesterol repletion partially restores insulin receptor binding and glucose 
uptake in ethanol-exposed neuronal cells. Therefore, ethanol-induced perturbations in membrane lipid 
composition contribute to insulin/IGF resistance in brain. However, cholesterol repletion did not fully 
restore insulin/IGF-1 responsiveness  in ethanol-exposed neurons. One possible explanation  is that, 
besides  cholesterol,  ethanol  depletes  a  variety  of  membrane  lipids,  including  sphingomyelin. 
Correspondingly, recent studies also demonstrated that ethanol-induced hepatic insulin resistance was 
associated with altered expression of genes utilized in lipid metabolism, including both synthetic and 
degradative pathways.  Int. J. Environ. Res. Public Health 2009, 6                 
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4. Ceramides Mediate Insulin Resistance 
 
Steatohepatitis, Insulin Resistance, and Toxic Lipid Generation  
 
To determine if hepatic insulin resistance was a consequence of hepatic steatosis, we measured 
insulin and IGF receptor binding, gene expression, and signaling in livers from several experimental 
models in which hepatic steatosis or steatohepatitis is a prominent feature including: 1) chronic ethanol 
feeding  (alcohol-induced  steatohepatitis;  ASH);  2)  diet  induced  obesity  (DIO)  with  non-alcoholic 
steatohepatitis  (NASH);  3)  high  fat  diet  (HFD)  feeding  without  obesity;  4)  nitrosamine-mediated 
injury; and 5) constitutive over-expression of the Hepatitis B virus X gene (HBx) in transgenic mouse 
livers. Without exception, steatohepatitis was associated with reduced insulin receptor (IR) binding, IR 
gene expression, IR tyrosine phosphorylation, IR tyrosine kinase activation, signaling through IRS-1, 
and insulin responsive gene expression, and increased oxidative stress and adduct (DNA, protein, and 
lipid) accumulation. In human cases of NASH, insulin sensitizer drug treatments that reduce severity 
of steatohepatitis increase insulin responsive gene expression in liver [62,63]. Therefore, irrespective 
of  cause,  hepatic  steatosis  and  steatohepatitis  have  pivotal  roles  in  the  pathogenesis  of  liver  
insulin resistance.  
Insulin stimulates lipogenesis, which results in increased triglyceride storage in the liver [64,65]. 
While this process is generally benign and well tolerated, disturbances in homeostasis caused by ER 
stress,  oxidative  damage,  mitochondrial  dysfunction,  inflammation,  and/or  altered  membrane  lipid 
composition  can  shift  the  balance  toward  a  state  of  insulin  resistance  [64,66].  Insulin  resistance 
promotes  lipolysis  [67],  and  lipolysis  generates  toxic  lipids,  i.e.,  ceramides,  which  further  impair 
insulin signaling, mitochondrial function, and cell viability [66,68,69]. We propose that this sequence 
of events establishes a reverberating loop of progressive hepatic dysfunction that could evolve toward 
end-stage liver disease. 
 
Ceramides as Culprits  
 
Ceramides are lipid signaling molecules that modulate positive or negative cellular responses such 
as, proliferation, motility, plasticity, inflammation, apoptosis, and insulin resistance [70]. Lipids stored 
in hepatocyes are mobilized by lipolysis and degradation of sphingomyelin. Ceramides are generated 
during biosynthesis and degradation of triglycerides and sphingomyelin [68,71-74]. Disease-associated 
lipolysis is a feature of insulin resistance, and can be initiated by critically high levels of ER stress and 
mt  dysfunction  [75-78].  In  such  states,  ceramides  cause  insulin  resistance  by  activating  pro-
inflammatory cytokines and inhibiting insulin-stimulated signaling through PI3 kinase-Akt [79-82]. In 
diet-induced obesity, the mechanisms of enhanced ceramide production in adipocytes and attendant 
insulin resistance have been well documented [70,73,74,83-85]. In contrast, there is little information 
about  the  role  of  ceramides  in  relation  to  hepatic  insulin  resistance.  To  address  this  issue,  we 
conducted experiments to determine whether: 1) ceramide exposure causes hepatic insulin resistance; 
2) chronic ethanol exposure or other models of steatohepatitis lead to increased pro-ceramide gene 
expression  in  liver; and 3) hepatic steatosis and steatohepatitis result  in  increased ceramide  levels 
(immunoreactivity) in liver and serum. The studies demonstrated that in vitro treatment with C2 or C6 Int. J. Environ. Res. Public Health 2009, 6                 
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synthetic ceramide significantly impairs hepatocellular viability, mt function, and insulin-stimulated 
signaling  through  Akt  and  GSK-3.  Therefore,  exogenous  ceramide  exposure  is  hepatotoxic  and 
causes hepatic insulin resistance.  
 
5. Factors Regulating Ceramide Biosynthesis and Accumulation in Liver 
 
Ceramides are enzymatically generated through the actions of several genes whose regulations are 
still  being  investigated.  To  assess  the  potential  role  of  ceramides  in  the  pathogenesis  of  insulin 
resistance in the context of hepatic steatosis or steatohepatitis, we used quantitative (q) RT-PCR to 
measure pro-ceramide mRNA levels in several models of steatohepatitis including ASH (rat), NASH 
(rat, mouse, human), and DIO (rat). Irrespective of the etiology of steatohepatitis, the mean levels of 
several pro-ceramide mRNA transcripts were significantly increased over control. In addition, by both 
dot blot analysis and ELISA, we detected significantly higher levels of ceramide immunoreactivity in 
liver and serum of  ASH, NASH, and DIO  models, and  in  humans with NASH. Moreover, recent 
studies demonstrated that hepatic and serum ceramide levels correlate with severity of alcohol-induced 
steatohepatitis  in  the  LE,  SD,  and  FS  rat  strains  (Figure  3).  These  studies  demonstrate  that  pro-
ceramide gene expression and hepatic and serum ceramide levels increase with steatohepatitis from 
various causes.  
 
Figure  3.  Genetic  factors  governing  degrees  of  alcohol-induced  hepatic  steatosis  and 
neurodegeneration correlate with liver and serum ceramide content as measured by ELISA 
or  dot  blot  analysis.  Immunoreactivity  was  detected  with  HRP  conjugated  secondary 
antibody and enhanced chemiluminescence reagents, and quantified by digital  imaging. 
Significant P-values are indicated over the bars.  
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Endogenous Brain Ceramide Production 
 
Many  studies,  including  our  own,  have  demonstrated  direct  toxic  and  degenerative  effects  of 
ethanol  using  in  vitro  models  [51,52,58,59].  Therefore,  ethanol  capable  of  bypassing  peripheral 
detoxification systems can directly cause CNS injury and degeneration by increasing oxidative stress, 
DNA damage, lipid peroxidation, and mt dysfunction, and perturbing membrane lipid composition, 
leading to increased insulin/IGF resistance [33,34,36]. CNS neurons and oligodendrocytes are insulin-
responsive  [17,22,26]  Insulin  and  IGF  promote  viability,  energy  metabolism,  neurotransmitter 
synthesis,  plasticity,  and  myelin  homeostasis  in  these  cell  types.  Metabolic  stresses  impair 
oligodendroglial functions, including myelin maintenance [23,27,29]. Since ceramides are generated in 
brain during myelin turnover and degradation, factors that impair oligodendroglial function would be 
expected to increase ceramide synthesis [86-90]. Locally increased ceramide production would worsen 
brain  insulin/IGF  resistance,  neuro-inflammation,  and  oxidative  stress  [70,72,74,80,85,91-95].  The 
degree to which this scenario mediates alcohol-related neurodegeneration, i.e., white matter atrophy 
and leukoencephalopathy, would likely correlate with inefficiency of peripheral (gastrointestinal and 
hepatic) detoxification systems or binge exposures that overwhelm the network. In essence, alcohol-
induced hepatotoxicity with increased generation of peripheral ceramides and other toxic lipids, would 
likely  mediate  their  adverse  effects  on  CNS  structure  and  function  via  a  liver-brain  axis  of 
neurodegeneration.  
 
Figure 4. Ceramides cause insulin resistance, acetylcholine deficits, energy depletion, and 
oxidative stress. Cultured CNS neuronal cells were exposed to vehicle (Veh), C2 or C6 
cytotoxic ceramides (50 mM), or C2D inactive ceramide for 24 hours. Gene expression 
was measured by qRT-PCR with results normalized to 18S rRNA. As indices of oxidative 
stress, (E) 4-hydroxynonenal (4-HNE) and (F) ubiquitin immunoreactivity were measured 
by ELISA [96].  
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Correspondingly,  exogenous  exposure  to  neurotoxic  ceramides  results  in  neuronal  insulin 
resistance, neurodegeneration, energy failure, and increased oxidative stress (Figure 4). 
 
6. Liver Brain Axis of Neurodegeneration 
 
Ceramides and the Liver-Brain Axis of Neurodegeneration 
 
Clinically,  ASH,  NASH,  and  viral  steatohepatitis  can  each  be  associated  with  cognitive  and 
neuropsychiatric  dysfunction  [97-103].  We  examined  insulin  signaling  mechanisms,  pro-ceramide 
gene expression, and ceramide levels in experimental models of steatohepatitis or hepatic steatosis, 
including  chronic  HFD  feeding,  peripheral  (i.p.)  nitrosamine  exposure  (sub-mutagenic  doses),  and 
DIO  with  T2DM  and  NASH,  all  of  which  have  histopathologic  and  biochemical  evidence  of 
neurodegeneration,  and  deficits  in  learning  and  memory  by  Morris  water  maze  testing  [104-108]. 
Steatohepatitis was associated with liver and brain insulin resistance manifested by reduced insulin 
receptor (IR) binding, IR gene expression, IR tyrosine kinase activation, and insulin responsive gene 
expression,  including  those  required  for  metabolism  or  neurotransmitter  synthesis  [104-110],  and 
increased oxidative stress. Using qRT-PCR analysis, we found that steatohepatitis was associated with 
up-regulated  expression  of  multiple  pro-ceramide  genes  in  liver  (Figure  5).  ELISA  and  dot  blot 
analyses demonstrated higher mean levels of ceramide immunoreactivity in liver and blood.  
 
Figure  5.  Genetic  factors  govern  shifts  in  hepatic  ceramide  gene  expression  levels 
associated with chronic ethanol exposure. FS, LE, and SD rats were chronically fed with 
control or ethanol-containing liquid diets for 8 weeks, and then livers were used to measure 
pro-ceramide gene expression by qRT-PCR. Example results are shown for (A) Ceramide 
Synthase  2  (Cer2)  and  (B)  sphingomyelinase  1  (SMPD1).  Significant  P-values  are 
indicated  over  the  bars.  In  addition,  asterisks  reflect  significant  differences  from  FS 
controls (*P < 0.05; **P < 0.01). Similar results have been obtained using various models 
of hepatic steatosis/steatohepatitis [107,110,111]. 
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Ethanol-fed rats with steatohepatitis developed CNS insulin resistance with neurodegeneration and 
cognitive impairment [11,12,16], but in that model, pro-ceramide gene expression was increased in 
both  liver  and  brain.  In  human  alcoholics,  white  matter  atrophy  and  degeneration  with  reduced 
expression of myelin-associated genes, and increased levels of oxidative stress were associated with 
increased expression of pro-ceramide genes (Figure 6) [35]. So, how could this be explained? 
 
Figure 6. Pro-ceramide gene expression in human controls and chronic alcoholic brains as 
measured  by  qRT-PCR  analysis.  RNA  was  isolated  from  frontal  lobes  of  postmortem 
brains  and  used  to  measure  (A)  ceramide  synthase  2  (CER2),  (B)  SPTLC2,  and  (C) 
Sphingomyelinase 3 (SMPD3). Results were normalize to 18S rRNA. Significant P-values 
are  shown  over  the  bars.  CER2  and  SPTLC2  generate  ceramide  via  a  biosynthetic 
pathway.  SPMD3  produces  ceramides  and  other  toxic  lipids  via  a  degradation  
pathway [35].  
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Since  toxic  lipids,  including  ceramides  readily  cross  the  blood-brain  barrier  and  cause  insulin 
resistance  by  interfering  with  critical  phosphorylation  events  [112-114]  and  activating  pro-
inflammatory  cytokines  [70,115,116],  we  conducted  several  experiments  designed  to  address  our 
hypothesis  about  the  potential  role  of  extra-CNS  (liver)-derived  ceramides  as  mediators  of 
neurodegeneration.  In  vitro  experiments  demonstrated  that  C2  or  C6  ceramide  exposures  cause 
neuronal  insulin  resistance  with  reduced  viability  and  neurotransmitter  function,  and  increased 
mitochondrial  dysfunction,  oxidative  stress,  DNA  damage,  and  lipid  peroxidation  (Figure  4)  [96]. 
Moreover,  preliminary  studies  showed  that  in  vivo  (i.p.)  ceramide  treatments  cause  brain  insulin 
resistance, neurodegeneration, cognitive-motor deficits that mimic features of chronic alcohol feeding, 
and later increased pro-ceramide gene expression in brain. Therefore, ceramides generated or delivered 
from extra-CNS sources can cause brain insulin resistance and thereby mediate neurodegeneration. In 
addition, exposure to exogenous ceramides could increase CNS expression of pro-ceramide genes.  
 
Figure  7.  Liver-brain  axis  of  neurodegeneration—Hypothesis.  Progressive  hepatic 
steatosis incites inflammation and pro-inflammatory cytokine activation. Attendant insulin 
resistance  initiates  a  lipolysis  and  lipid  disequilibrium  cascade,  leading  to  increased 
production and accumulation of ceramides. Ceramides are cytotoxic and promote insulin 
resistance, and their lipid solubility enables ready transfer across the blood-brain barrier to 
cause  CNS  insulin  resistance  and  neurodegeneration  with  loss  of  neurons  and 
oligodendrocytes. Ethanol’s lipid solubility enables it to exert direct neurotoxic effects, and 
cause brain insulin resistance.  
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7. Conclusions 
 
Chronic  alcohol  exposure  resulting  in  steatohepatitis,  ER  stress,  and  persistent  hepatic  injury, 
promotes lipolysis and increased generation of toxic lipids, including ceramides. Ceramides exacerbate 
liver injury by causing insulin resistance, oxidative stress, and pro-inflammatory cytokine activation. 
Ceramides that are released into peripheral blood, and lipid soluble and therefore can readily cross the 
blood-brain barrier. In the CNS, ceramides initiate a complex cascade of neurodegeneration mediated 
by insulin resistance, inflammation, and oxidative stress. CNS insulin resistance leads to neuronal loss 
and impaired oligodendrocyte function. Attendant myelin degradation leads to increased CNS toxic 
lipid production and worsening of neurodegeneration. In addition, direct neurotoxic effects of alcohol 
and its metabolites, which impair mitochondrial function, reduce membrane integrity, and increase 
oxidative stress also contributes to neurodegeneration.  
Brain insulin resistance leads to neuronal loss and impaired neurotransmitter function required for 
plasticity, learning, and memory. In addition, brain insulin resistance impairs oligodendrocyte survival 
and  function,  resulting  in  reduced  myelin  integrity,  and  increased  generation  of  ceramides,  which 
further increase brain insulin resistance, neuro-inflammation, oxidative stress, and neurodegeneration. 
These concepts open an exciting new chapter on disease mechanisms and strategies for developing 
non-invasive tools to monitor proneness and progression of alcoholic neurodegeneration. Our over-
arching hypothesis about how alcohol mis-use causes neurodegeneration, both directly and via the 
liver-brain axis is diagramed in Figure 7. It is noteworthy that dietary indiscretions leading to hepatic 
steatosis, i.e., chronic high caloric intake, significantly compound these problems and contribute to the 
liver-brain axis of neurodegeneration. 
 
References 
 
1.  Diehl, A.M.; Thorgeirsson, S.S.; Steer, C.J. Ethanol inhibits liver regeneration in rats without 
reducing transcripts of key protooncogenes. Gastroenterology 1990, 99, 1105-1112. 
2.  Duguay, L.; Coutu, D.; Hetu, C.; Joly, J.G. Inhibition of liver regeneration by chronic alcohol 
administration. Gut 1982, 23, 8-13. 
3.  Wands, J.R.; Carter, E.A.; Bucher, N.L.; Isselbacher, K.J. Inhibition of hepatic regeneration in 
rats by acute and chronic ethanol intoxication. Gastroenterology 1979, 77, 528-531. 
4.  Wands, J.R.; Carter, E.A.; Bucher, N.L.; Isselbacher, K.J. Effect of acute and chronic ethanol 
intoxication on hepatic regeneration. Adv. Exp. Med. Biol. 1980, 132, 663-670. 
5.  Banerjee, K.; Mohr, L.; Wands, J.R.; de la Monte, S.M. Ethanol inhibition of insulin signaling in 
hepatocellular carcinoma cells. Alcohol Clin. Exp. Res. 1998, 22, 2093-2101. 
6.  Carter,  E.A.;  Wands,  J.R.  Ethanol  inhibits  hormone  stimulated  hepatocyte  DNA  synthesis. 
Biochem. Biophys. Res. Commun. 1985, 128, 767-774. 
7.  Li,  W.;  Liu,  X.;  Yanoff,  M.  Phosphatidylcholine  hydrolysis  and  DNA  synthesis  in  cultured 
retinal capillary pericytes. Microvasc. Res. 1995, 49, 350-363. 
8.  Mohr, L.; Tanaka, S.; Wands, J.R. Ethanol inhibits hepatocyte proliferation in insulin receptor 
substrate 1 transgenic mice. Gastroenterology 1998, 115, 1558-1565. Int. J. Environ. Res. Public Health 2009, 6                 
 
2068 
9.  Sasaki, Y.; Hayashi, N.; Ito, T.; Fusamoto, H.; Kamada, T.; Wands, J.R. Influence of ethanol on 
insulin receptor substrate-1-mediated signal transduction during rat liver regeneration. Alcohol 
Alcoholism 1994, 1, 99-106. 
10.  Sasaki, Y.; Wands, J.R. Ethanol impairs insulin receptor substrate-1 mediated signal transduction 
during rat liver regeneration. Biochem. Biophys. Res. Commun. 1994, 199, 403-409. 
11.  de la Monte, S.M.; Yeon, J.E.; Tong, M.; Longato, L.; Chaudhry, R.; Pang, M.Y.; Duan, K.; 
Wands, J.R. Insulin resistance in experimental alcohol-induced liver disease. J. Gastroenterol. 
Hepatol. 2008, 23, e477-86. 
12.  Pang, M.; de la Monte, S.M.; Longato, L.; Tong, M.; He, J.; Chaudhry, R.; Duan, K.; Ouh, J.; 
Wands,  J.R.  PPARdelta  agonist  attenuates  alcohol-induced  hepatic  insulin  resistance  and 
improves liver injury and repair. J. Hepatol. 2009, 50, 1192-1201. 
13.  Harper, C. The neuropathology of alcohol-specific brain damage, or does alcohol damage the 
brain? J. Neuropathol. Exp. Neurol. 1998, 57, 101-110. 
14.  Harper, C.; Dixon, G.; Sheedy, D.; Garrick, T. Neuropathological alterations in alcoholic brains. 
Studies  arising  from  the  New  South  Wales  Tissue  Resource  Centre.  Prog. 
Neuropsychopharmacol. Biol. Psychiat. 2003, 27, 951-961. 
15.  de la Monte, S.M. Disproportionate atrophy of cerebral white matter in chronic alcoholics. Arch. 
Neurol. 1988, 45, 990-992. 
16.  Cohen, A.C.; Tong, M.; Wands, J.R.; de la Monte, S.M. Insulin and insulin-like growth factor 
resistance with  neurodegeneration  in an adult chronic ethanol exposure  model.  Alcohol Clin. 
Exp. Res. 2007, 31, 1558-1573. 
17.  de la Monte, S.M.; Wands, J.R. Review of insulin and insulin-like growth factor expression, 
signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. 
Alzheimers Dis. 2005, 7, 45-61. 
18.  Chang, L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. 
Mol. Med. 2004, 10, 65-71. 
19.  Giovannone, B.; Scaldaferri, M.L.; Federici, M.; Porzio, O.; Lauro, D.; Fusco, A.; Sbraccia, P.; 
Borboni, P.; Lauro, R.; Sesti, G. Insulin receptor substrate (IRS) transduction system: distinct 
and overlapping signaling potential. Diabetes Metab. Res. Rev. 2000, 16, 434-441. 
20.  Gammeltoft, S.; Fehlmann, M.; Van, O.E. Insulin receptors in the mammalian central nervous 
system: binding characteristics and subunit structure. Biochimie 1985, 67, 1147-1153. 
21.  Hill, J.M.; Lesniak, M.A.; Pert, C.B.; Roth, J. Autoradiographic localization of insulin receptors 
in rat brain: prominence in olfactory and limbic areas. Neuroscience 1986, 17, 1127-1138. 
22.  Broughton, S.K.; Chen, H.; Riddle, A.; Kuhn, S.E.; Nagalla, S.; Roberts, C.T., Jr.; Back, S.A. 
Large-scale  generation  of  highly  enriched  neural  stem-cell-derived  oligodendroglial  cultures: 
maturation-dependent differences in insulin-like growth factor-mediated signal transduction. J. 
Neurochem. 2007, 100, 628-638. 
23.  Freude, S.; Leeser, U.; Muller, M.; Hettich, M.M.; Udelhoven, M.; Schilbach, K.; Tobe, K.; 
Kadowaki, T.; Kohler, C.; Schroder, H.; Krone, W.; Bruning, J.C.; Schubert, M. IRS-2 branch of 
IGF-1 receptor signaling is essential for appropriate timing of myelination. J. Neurochem. 2008, 
107, 907-917. Int. J. Environ. Res. Public Health 2009, 6                 
 
2069 
24.  Joseph  D'Ercole,  A.;  Ye,  P.  Expanding  the  mind:  insulin-like  growth  factor  I  and  brain 
development. Endocrinology 2008, 149, 5958-5962. 
25.  Schubert, M.; Brazil, D.P.; Burks, D.J.; Kushner, J.A.; Ye, J.; Flint, C.L.; Farhang-Fallah, J.; 
Dikkes, P.; Warot, X.M.; Rio, C.; Corfas, G.; White, M.F. Insulin receptor substrate-2 deficiency 
impairs brain growth and promotes tau phosphorylation. J. Neurosci. 2003, 23, 7084-7092. 
26.  Chesik,  D.;  de  Keyser,  J.;  Wilczak,  N.  Insulin-like  growth  factor  system  regulates 
oligodendroglial cell behavior: therapeutic potential in CNS. J. Mol. Neurosci. 2008, 35, 81-90. 
27.  Gong, X.; Xie, Z.; Zuo, H. Invivo insulin deficiency as a potential etiology for demyelinating 
disease. Med. Hypotheses 2008, 71, 399-403. 
28.  Liang,  G.;  Cline,  G.W.;  Macica,  C.M.  IGF-1  stimulates  de  novo  fatty  acid  biosynthesis  by 
Schwann cells during myelination. Glia 2007, 55, 632-641. 
29.  Ye, P.; Kollias, G.; D'Ercole, A.J. Insulin-like growth factor-I ameliorates demyelination induced 
by tumor necrosis factor-alpha in transgenic mice. J. Neurosci. Res. 2007, 85, 712-722. 
30.  Wands, J.R.; Mohr, L.; Banerjee, K.; Ganju, N.; Tanaka, S.; de la Monte, S.M. Ethanol and IRS-1 
protein  in  the  liver  and  brain.  In  Proceedings  on  Signal  Transduction  and  Alcohol,  Lund, 
Sweden, 2001. 
31.  Yeon,  J.E.;  Califano,  S.;  Xu,  J.;  Wands,  J.R.;  De  La  Monte,  S.M.  Potential  role  of  PTEN 
phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 2003, 38, 703-714. 
32.  Ronis,  M.J.;  Butura,  A.;  Korourian,  S.;  Shankar,  K.;  Simpson,  P.;  Badeaux,  J.;  Albano,  E.; 
Ingelman-Sundberg,  M.;  Badger,  T.M.  Cytokine  and  chemokine  expression  associated  with 
steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition.  Exp. 
Biol. Med. (Maywood) 2008, 233, 344-355. 
33.  de  la  Monte,  S.M.;  Wands,  J.R.  Chronic  gestational  exposure  to  ethanol  impairs  insulin-
stimulated survival and mitochondrial function in cerebellar neurons. CMLS, Cell Mol. Life Sci. 
2002, 59, 882-893. 
34.  de la Monte, S.M.; Xu, X.J.; Wands, J.R. Ethanol inhibits insulin expression and actions in the 
developing brain. Cell Mol. Life Sci. 2005, 62, 1131-1145. 
35.  de la Monte, S.M.; Tong, M.; Cohen, A.C.; Sheedy, D.; Harper, C.; Wands, J.R. Insulin and 
insulin-like  growth  factor  resistance  in  alcoholic  neurodegeneration.  Alcohol  Clin.  Exp.  Res. 
2008, 32, 1630-1644. 
36.  Soscia, S.J.; Tong, M.; Xu, X.J.; Cohen, A.C.; Chu, J.; Wands, J.R.; de la Monte, S.M. Chronic 
gestational  exposure  to  ethanol  causes  insulin  and  IGF  resistance  and  impairs  acetylcholine 
homeostasis in the brain. Cell Mol. Life Sci. 2006, 63, 2039-2056. 
37.  Ronis,  M.J.;  Wands,  J.R.;  Badger,  T.M.;  de  la  Monte,  S.M.;  Lang,  C.H.;  Calissendorff,  J. 
Alcohol-induced disruption of endocrine signaling. Alcohol Clin. Exp. Res. 2007, 31, 1269-1285. 
38.  Enomoto,  N.;  Takei,  Y.;  Hirose,  M.;  Konno,  A.;  Shibuya,  T.;  Matsuyama,  S.;  Suzuki,  S.; 
Kitamura,  K.I.;  Sato,  N.  Prevention  of  ethanol-induced  liver  injury  in  rats  by  an  agonist  of 
peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther. 2003, 
306, 846-854. Int. J. Environ. Res. Public Health 2009, 6                 
 
2070 
39.  Onishi, Y.; Honda, M.; Ogihara, T.; Sakoda, H.; Anai, M.; Fujishiro, M.; Ono, H.; Shojima, N.; 
Fukushima,  Y.;  Inukai,  K.;  Katagiri,  H.;  Kikuchi,  M.;  Oka,  Y.;  Asano,  T.  Ethanol  feeding 
induces  insulin  resistance  with  enhanced  PI  3-kinase  activation.  Biochem.  Biophys.  Res. 
Commun. 2003, 303, 788-794. 
40.  Patel, B.C.; D'Arville, C.; Iwahashi, M.; Simon, F.R. Impairment of hepatic insulin receptors 
during chronic ethanol administration. Am. J. Physiol. 1991, 261, G199-205. 
41.  Sadri,  P.;  Legare,  D.J.;  Takayama,  S.;  Lautt,  W.W.  Increased  incidence  of  hepatic  insulin-
sensitizing substance (HISS)-dependent insulin resistance in female rats prenatally exposed to 
ethanol. Can. J. Physiol. Pharmacol. 2005, 83, 383-387. 
42.  Tomita, K.; Azuma, T.; Kitamura, N.; Nishida, J.; Tamiya, G.; Oka, A.; Inokuchi, S.; Nishimura, 
T.; Suematsu, M.; Ishii, H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-
regulation of c-Met. Gastroenterology 2004, 126, 873-885. 
43.  Yao, X.H.; Chen, L.; Nyomba, B.L. Adult rats prenatally exposed to ethanol have  increased 
gluconeogenesis and impaired insulin response of hepatic gluconeogenic genes. J. Appl. Physiol. 
2006, 100, 642-648. 
44.  Li,  X.L.;  Man,  K.;  Ng,  K.T.;  Sun,  C.K.;  Lo,  C.M.;  Fan,  S.T.  The  influence  of 
phosphatidylinositol  3-kinase/Akt  pathway  on  the  ischemic  injury  during  rat  liver  graft 
preservation. Am. J. Transplant. 2005, 5, 1264-1275. 
45.  Michl,  P.;  Downward,  J.  Mechanisms  of  disease:  PI3K/AKT  signaling  in  gastrointestinal 
cancers. Z. Gastroenterol. 2005, 43, 1133-1139. 
46.  Roberts, R.A.; James, N.H.; Cosulich, S.C. The role of protein kinase B and mitogen-activated 
protein  kinase  in  epidermal  growth  factor  and  tumor  necrosis  factor  alpha-mediated  rat 
hepatocyte survival and apoptosis. Hepatology 2000, 31, 420-427. 
47.  Rust,  C.;  Bauchmuller,  K.;  Fickert,  P.;  Fuchsbichler,  A.;  Beuers,  U.  Phosphatidylinositol  3-
kinase-dependent  signaling  modulates  taurochenodeoxycholic  acid-induced  liver  injury  and 
cholestasis in perfused rat livers. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289, G88-94. 
48.  Valverde,  A.M.;  Fabregat,  I.;  Burks,  D.J.;  White,  M.F.;  Benito,  M.  IRS-2  mediates  the 
antiapoptotic effect of insulin in neonatal hepatocytes. Hepatology 2004, 40, 1285-1294. 
49.  Carmiel-Haggai, M.; Cederbaum, A.I.; Nieto, N. Binge ethanol exposure increases liver injury in 
obese rats. Gastroenterology 2003, 125, 1818-1833. 
50.  McVicker, B.L.; Tuma, D.J.; Kubik, J.L.; Tuma, P.L.; Casey, C.A. Ethanol-induced apoptosis in 
polarized hepatic cells possibly through regulation of the Fas pathway. Alcohol Clin. Exp. Res. 
2006, 30, 1906-1915. 
51.  de la Monte, S.M.; Ganju, N.; Banerjee, K.; Brown, N.V.; Luong, T.; Wands, J.R. Partial rescue 
of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. 
Alcohol Clin. Exp. Res. 2000, 24, 716-726. 
52.  de  la  Monte,  S.M.;  Neely,  T.R.;  Cannon,  J.;  Wands,  J.R.  Ethanol  impairs  insulin-stimulated 
mitochondrial function in cerebellar granule neurons. Cell Mol. Life Sci. 2001, 58, 1950-1960. 
53.  Hallak, H.; Seiler, A.E.; Green, J.S.; Henderson, A.; Ross, B.N.; Rubin, R. Inhibition of insulin-
like growth factor-I signaling by ethanol in neuronal cells. Alcohol Clin. Exp. Res. 2001, 25, 
1058-1064. Int. J. Environ. Res. Public Health 2009, 6                 
 
2071 
54.  Zhang, F.X.; Rubin, R.; Rooney, T.A. Ethanol induces apoptosis in cerebellar granule neurons by 
inhibiting insulin-like growth factor 1 signaling. J. Neurochem. 1998, 71, 196-204. 
55.  Spaissman, A.; Tong, M.; de la Monte, S.M. Acetaldehyde-Mediated neuronal apoptosis and 
mitochondrial  dysfunction:  relevance  to  fetal  alcohol  syndrome.  J.  Neurochem.  2009, 
(Submitted). 
56.  Ramachandran,  V.;  Perez,  A.;  Chen,  J.;  Senthil,  D.;  Schenker,  S.;  Henderson,  G.I.  In  utero 
ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in 
fetal brain: a potential role for 4- hydroxynonenal. Alcohol Clin. Exp. Res. 2001, 25, 862-871. 
57.  Ikonomidou, C.; Bittigau, P.; Ishimaru, M.J.; Wozniak, D.F.; Koch, C.; Genz, K.; Price, M.T.; 
Stefovska, V.; Horster, F.; Tenkova, T.; Dikranian, K.; Olney, J.W. Ethanol-induced apoptotic 
neurodegeneration and fetal alcohol syndrome. Science 2000, 287, 1056-1060. 
58.  de  la  Monte,  S.M.;  Wands,  J.R.  Mitochondrial  DNA  damage  and  impaired  mitochondrial 
function contribute to apoptosis of  insulin-stimulated ethanol-exposed neuronal cells.  Alcohol 
Clin. Exp. Res. 2001, 25, 898-906. 
59.  Xu, J.; Yeon, J.E.; Chang, H.; Tison, G.; Chen, G.J.; Wands, J.; de la Monte, S. Ethanol impairs 
insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J. Biol. 
Chem. 2003, 278, 26929-26937. 
60.  Marco, C.; Ceacero, F.; Gonzalez-Pacanowska, D.; Garcia-Peregrin, E.; Segovia, J.L. Alterations 
induced  by chronic ethanol treatment on lipid composition of  microsomes,  mitochondria and 
myelin from neonatal chick liver and brain. Biochem. Int. 1986, 12, 51-60. 
61.  Muller,  G.;  Jung,  C.;  Frick,  W.;  Bandlow,  W.;  Kramer,  W.  Interaction  of 
phosphatidylinositolglycan(-peptides) with plasma membrane lipid rafts triggers insulin-mimetic 
signaling in rat adipocytes. Arch. Biochem. Biophys. 2002, 408, 7-16. 
62.  Lutchman, G.; Promrat, K.; Kleiner, D.E.; Heller, T.; Ghany, M.G.; Yanovski, J.A.; Liang, T.J.; 
Hoofnagle,  J.H.  Changes  in  serum  adipokine  levels  during  pioglitazone  treatment  for 
nonalcoholic  steatohepatitis:  relationship  to  histological  improvement.  Clin.  Gastroenterol. 
Hepatol. 2006, 4, 1048-1052. 
63.  Promrat, K.; Lutchman, G.; Uwaifo, G.I.; Freedman, R.J.; Soza, A.; Heller, T.; Doo, E.; Ghany, 
M.; Premkumar, A.; Park, Y.; Liang, T.J.; Yanovski, J.A.; Kleiner, D.E.; Hoofnagle, J.H. A pilot 
study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39, 188-196. 
64.  Capeau, J. Insulin resistance and steatosis in humans. Diabetes Metab. 2008, 34, 649-657. 
65.  Leonard, B.L.; Watson, R.N.; Loomes, K.M.; Phillips, A.R.; Cooper, G.J. Insulin resistance in 
the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes.  Acta 
Diabetol. 2005, 42, 162-170. 
66.  Kraegen, E.W.; Cooney, G.J. Free fatty acids and skeletal muscle insulin resistance. Curr. Opin. 
Lipidol. 2008, 19, 235-241. 
67.  Kao, Y.; Youson, J.H.; Holmes, J.A.; Al-Mahrouki, A.; Sheridan, M.A. Effects of insulin on 
lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus. 
Gen. Comp. Endocrinol. 1999, 114, 405-414. 
68.  Holland,  W.L.;  Summers,  S.A.  Sphingolipids,  insulin  resistance,  and  metabolic  disease:  new 
insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 2008, 29, 381-402. Int. J. Environ. Res. Public Health 2009, 6                 
 
2072 
69.  Langeveld, M.; Aerts, J.M. Glycosphingolipids and insulin resistance. Prog. Lipid. Res. 2009, 
48, 196-205.  
70.  Summers,  S.A.  Ceramides  in  insulin  resistance  and  lipotoxicity.  Prog.  Lipid.  Res.  2006,  45,  
42-72. 
71.  Boden, G. Ceramide: a contributor to insulin resistance or an innocent bystander? Diabetologia 
2008, 51, 1095-1096. 
72.  Delarue, J.; Magnan, C. Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. 
Care 2007, 10, 142-148. 
73.  Holland, W.L.; Brozinick, J.T.; Wang, L.P.; Hawkins, E.D.; Sargent, K.M.; Liu, Y.; Narra, K.; 
Hoehn,  K.L.;  Knotts,  T.A.;  Siesky,  A.;  Nelson,  D.H.;  Karathanasis,  S.K.;  Fontenot,  G.K.; 
Birnbaum, M.J.; Summers, S.A. Inhibition of ceramide synthesis ameliorates glucocorticoid-, 
saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167-179. 
74.  Holland,  W.L.;  Knotts, T.A.;  Chavez,  J.A.;  Wang,  L.P.;  Hoehn,  K.L.;  Summers,  S.A.  Lipid 
mediators of insulin resistance. Nutr. Rev. 2007, 65, S39-46. 
75.  Anderson,  N.;  Borlak,  J.  Molecular  mechanisms  and  therapeutic  targets  in  steatosis  and 
steatohepatitis. Pharmacol. Rev. 2008, 60, 311-357. 
76.  Kaplowitz, N.; Than, T.A.; Shinohara, M.; Ji, C. Endoplasmic reticulum stress and liver injury. 
Semin. Liver Dis. 2007, 27, 367-377. 
77.  Malhi, H.; Gores, G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. 
Semin. Liver Dis. 2008, 28, 360-369. 
78.  Sundar Rajan, S.; Srinivasan, V.; Balasubramanyam, M.; Tatu, U. Endoplasmic reticulum (ER) 
stress & diabetes. Indian J. Med. Res. 2007, 125, 411-424. 
79.  Bourbon, N.A.; Sandirasegarane, L.; Kester, M. Ceramide-induced inhibition of Akt is mediated 
through  protein  kinase  Czeta:  implications  for  growth  arrest.  J.  Biol.  Chem.  2002,  277,  
3286-3292. 
80.  Hajduch, E.; Balendran, A.; Batty, I.H.; Litherland, G.J.; Blair, A.S.; Downes, C.P.; Hundal, H.S. 
Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a 
loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001, 44, 173-183. 
81.  Nogueira, T.C.; Anhe, G.F.; Carvalho, C.R.; Curi, R.; Bordin, S.; Carpinelli, A.R. Involvement 
of  phosphatidylinositol-3  kinase/AKT/PKCzeta/lambda  pathway  in  the  effect of  palmitate  on 
glucose-induced insulin secretion. Pancreas 2008, 37, 309-315. 
82.  Powell, D.J.; Hajduch, E.; Kular, G.; Hundal, H.S. Ceramide disables 3-phosphoinositide binding 
to the  pleckstrin  homology  domain  of  protein  kinase  B  (PKB)/Akt  by  a  PKCzeta-dependent 
mechanism. Mol. Cell Biol. 2003, 23, 7794-7808. 
83.  Consitt,  L.A.;  Bell,  J.A.;  Houmard,  J.A.  Intramuscular  lipid  metabolism,  insulin  action,  and 
obesity. IUBMB Life 2009, 61, 47-55.  
84.  Vistisen, B.; Hellgren, L.I.; Vadset, T.; Scheede-Bergdahl, C.; Helge, J.W.; Dela, F.; Stallknecht, 
B. Effect of gender on lipid-induced insulin resistance in obese subjects. Eur. J. Endocrinol. 
2008, 158, 61-68. 
85.  Zierath, J.R. The path to insulin resistance: paved with ceramides? Cell Metab. 2007, 5, 161-163. 
86.  Adibhatla, R.M.; Hatcher, J.F. Altered lipid metabolism in brain injury and disorders. Subcell 
Biochem. 2008, 49, 241-268. Int. J. Environ. Res. Public Health 2009, 6                 
 
2073 
87.  Blakemore,  W.F.;  Franklin,  R.J.  Remyelination  in  experimental  models  of  toxin-induced 
demyelination. Curr. Top Microbiol. Immunol. 2008, 318, 193-212. 
88.  Daigo, M.; Arai, Y.; Oshida, K.; Kitamura, Y.; Hayashi, M.; Shimizu, T.; Yamashiro, Y. Effect 
of hypoxic-ischemic injury on serine palmitoyltransferase activity in the developing rat brain. 
Pathobiology 2008, 75, 330-334. 
89.  Soeda,  S.;  Tsuji,  Y.;  Ochiai,  T.;  Mishima,  K.;  Iwasaki,  K.;  Fujiwara,  M.;  Yokomatsu,  T.; 
Murano, T.; Shibuya, S.; Shimeno, H. Inhibition of sphingomyelinase activity helps to prevent 
neuron death caused by ischemic stress. Neurochem. Int. 2004, 45, 619-626. 
90.  Soriano,  J.M.;  Gonzalez,  L.;  Catala,  A.I.  Mechanism  of  action  of  sphingolipids  and  their 
metabolites in the toxicity of fumonisin B1. Prog. Lipid. Res. 2005, 44, 345-356. 
91.  Adams,  J.M.,  II;  Pratipanawatr,  T.;  Berria,  R.;  Wang,  E.;  DeFronzo,  R.A.;  Sullards,  M.C.; 
Mandarino, L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant 
humans. Diabetes 2004, 53, 25-31. 
92.  Aerts, J.M.; Ottenhoff, R.; Powlson, A.S.; Grefhorst, A.; van Eijk, M.; Dubbelhuis, P.F.; Aten, J.; 
Kuipers,  F.;  Serlie,  M.J.;  Wennekes,  T.;  Sethi,  J.K.;  O'Rahilly,  S.;  Overkleeft,  H.S. 
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 
2007, 56, 1341-1349. 
93.  JeBailey, L.; Wanono, O.; Niu, W.; Roessler, J.; Rudich, A.; Klip, A. Ceramide- and oxidant-
induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling 
in muscle cells. Diabetes 2007, 56, 394-403. 
94.  Schmitz-Peiffer, C.; Craig, D.L.; Biden, T.J. Ceramide generation is sufficient to account for the 
inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with 
palmitate. J. Biol. Chem. 1999, 274, 24202-24210. 
95.  Teruel, T.; Hernandez, R.; Lorenzo, M. Ceramide mediates insulin resistance by tumor necrosis 
factor-alpha  in  brown  adipocytes  by  maintaining  Akt  in  an  inactive  dephosphorylated  state. 
Diabetes 2001, 50, 2563-25671. 
96.  Tong,  M.;  de  la  Monte,  S.M.  Mechanisms  of  ceramide-mediated  neurodegeneration.  J. 
Alzheimers Dis. 2009, 16, 705-714. 
97.  Schmidt, K.S.; Gallo, J.L.; Ferri, C.; Giovannetti, T.; Sestito, N.; Libon, D.J.; Schmidt, P.S. The 
neuropsychological  profile  of  alcohol-related  dementia  suggests  cortical  and  subcortical 
pathology. Dement. Geriatr. Cogn. Disord 2005, 20, 286-291. 
98.  Kopelman, M.D.; Thomson, A.D.; Guerrini, I.; Marshall, E.J. The Korsakoff syndrome: clinical 
aspects, psychology and treatment. Alcohol Alcoholism 2009, 44, 148-154. 
99.  Elwing, J.E.; Lustman, P.J.; Wang, H.L.; Clouse, R.E. Depression, anxiety, and nonalcoholic 
steatohepatitis. Psychosom. Med. 2006, 68, 563-569. 
100.  Loftis,  J.M.;  Huckans,  M.;  Ruimy,  S.;  Hinrichs,  D.J.;  Hauser,  P.  Depressive  symptoms  in 
patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta 
and tumor necrosis factor-alpha. Neurosci. Lett. 2008, 430, 264-268. 
101.  Perry,  W.;  Hilsabeck,  R.C.;  Hassanein,  T.I.  Cognitive  dysfunction  in  chronic  hepatitis  C:  a 
review. Dig. Dis. Sci. 2008, 53, 307-321. Int. J. Environ. Res. Public Health 2009, 6                 
 
2074 
102.  Karaivazoglou,  K.;  Assimakopoulos,  K.;  Thomopoulos,  K.;  Theocharis,  G.;  Messinis,  L.; 
Sakellaropoulos,  G.;  Labropoulou-Karatza,  C.  Neuropsychological  function  in  Greek  patients 
with chronic hepatitis C. Liver Int. 2007, 27, 798-805. 
103.  Weiss, J.J.; Gorman, J.M. Psychiatric behavioral aspects of comanagement of hepatitis C virus 
and HIV. Curr. HIV/AIDS Rep. 2006, 3, 176-181. 
104.  de la Monte, S.M.; Tong, M.; Lester-Coll, N.; Plater, M., Jr.; Wands, J.R. Therapeutic rescue of 
neurodegeneration  in  experimental  type  3  diabetes:  relevance  to  Alzheimer's  disease.  J. 
Alzheimers Dis. 2006, 10, 89-109. 
105.  Lester-Coll,  N.;  Rivera,  E.J.;  Soscia,  S.J.;  Doiron,  K.;  Wands,  J.R.;  de  la  Monte,  S.M. 
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. 
J. Alzheimers Dis. 2006, 9, 13-33. 
106.  Tong, M.; Lawton, M.; Neusner, A.; Longato, L.; Wands, J.R.; de la Monte, S.M. Nitrosamine-
mediated  type  2  diabetes  mellitus,  hepatic  steatosis,  and  alzheimer-type  neurodegeneration: 
Potential  role  of  environmental  exposures  in  our  insulin  resistance  diseases  pandemic.  J. 
Alzheimers Dis. 2009, (In Press). 
107.  Lyn-Cook, L.E.; Lawton, M.; Tong, M.; Silbermann, E.; Longato, L.; Jiao, P.; Mark, P.; Wands, 
J.R.;  Xu,  H.;  de  la  Monte,  S.M.  Hepatic  ceramide  mediates  brain  insulin  resistance  and 
neurodegeneration in obesity with type 2 diabetes mellitus and Non-alcoholoic steatohepatitis. J. 
Alzheimers Dis. 2008, (Submitted). 
108.  Moroz,  N.;  Tong,  M.;  Longato,  L.;  Xu,  H.;  de  la  Monte,  S.M.  Limited  Alzheimer-type 
neurodegeneration  in  experimental  obesity  and  Type  2  diabetes  mellitus.  J.  Alzheimers  Dis. 
2008, 15, 29-44. 
109.  Tong,  M.;  Longato,  L.;  de  la  Monte,  S.M.  Nitrosamine  exposure  exacerbates  high  fat  diet-
mediated neurodegeneration. BMC Cell Biol. 2009, (Under Review). 
110.  Tong, M.; Neusner, A.; Longato, L.; Lawton, M.; Wands, J.R.; de la Monte, S.M. Nitrosamine 
Exposure  Causes  Insulin  Resistance  Diseases:  Relevance  to  Type  2  Diabetes  Mellitus,  Non-
Alcoholic  Steatohepatitis,  and  Alzheimer's  Disease.  J.  Alzheimers  Dis.  2009,  Jun  19,  (Epub 
ahead of print). 
111.  Tong, M.; Neusner, A.; Longato, L.; Lawton, M.; Wands, J.R.; de la Monte, S.M. Nitosamine 
exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic 
steatohepatitis, and Alzheimer disease. J. Alzheimers Dis. 2009, (In Press). 
112.  Arboleda, G.; Huang, T.J.; Waters, C.; Verkhratsky, A.; Fernyhough, P.; Gibson, R.M. Insulin-
like  growth  factor-1-dependent  maintenance  of  neuronal  metabolism  through  the 
phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur. J. 
Neurosci. 2007, 25, 3030-3038. 
113.  Chalfant, C.E.; Kishikawa, K.; Mumby, M.C.; Kamibayashi, C.; Bielawska, A.; Hannun, Y.A. 
Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is 
stereospecific and regulated by phosphatidic acid. J. Biol. Chem. 1999, 274, 20313-20317. 
114.  Liu, B.; Obeid, L.M.; Hannun, Y.A. Sphingomyelinases in cell regulation. Semin. Cell Dev. Biol. 
1997, 8, 311-322. 
115.  Bryan, L.; Kordula, T.; Spiegel, S.; Milstien, S. Regulation and functions of sphingosine kinases 
in the brain. Biochim. Biophys. Acta 2008, 1781, 459-466. Int. J. Environ. Res. Public Health 2009, 6                 
 
2075 
116.  Van Brocklyn, J.R. Sphingolipid signaling pathways as potential therapeutic targets in gliomas. 
Mini. Rev. Med. Chem. 2007, 7, 984-990. 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This  article  is  an  open-access  article  distributed  under  the  terms  and  conditions  of  the  Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 